87 related articles for article (PubMed ID: 34911330)
1. Advanced stages of classical Hodgkin lymphoma - first-line treatment options.
Mociková H
Klin Onkol; 2021; 34(6):450-454. PubMed ID: 34911330
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Bartlett NL
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
[TBL] [Abstract][Full Text] [Related]
3. Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective.
Yasenchak C; Liu N; Beeks A; Fanale M; Robert N; He D; Yu KS
JCO Oncol Pract; 2023 Oct; 19(10):860-870. PubMed ID: 37651672
[TBL] [Abstract][Full Text] [Related]
4. Treatment Strategies in Advanced-Stage Hodgkin Lymphoma.
Dann EJ; Casasnovas RO
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893177
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
[TBL] [Abstract][Full Text] [Related]
6. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
Ferhanoglu B; Ozbalak M
Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
[TBL] [Abstract][Full Text] [Related]
7. Management of limited-stage Hodgkin lymphoma.
Al-Juhaishi T; Ahmed S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):500-509. PubMed ID: 38066938
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin lymphoma treatment for older persons in the modern era.
Evens AM; McKenna M; Ryu Tiger YK; Upshaw JN
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):483-499. PubMed ID: 38066840
[TBL] [Abstract][Full Text] [Related]
9. Where does PD-1 blockade fit in HL therapy?
Herrera AF
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin lymphoma: Focus on evolving treatment paradigms.
Roswarski JL; Longo DL
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
[TBL] [Abstract][Full Text] [Related]
11. Toward a cure for cHL without chemotherapy.
Lynch RC
Blood; 2024 Feb; 143(9):741-742. PubMed ID: 38421817
[No Abstract] [Full Text] [Related]
12. Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.
Longley J; Johnson PWM
Hematol Oncol; 2021 Jun; 39 Suppl 1():39-45. PubMed ID: 34105815
[TBL] [Abstract][Full Text] [Related]
13. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC; Ujjani CS; Poh C; Warren EH; Smith SD; Shadman M; Till B; Raghunathan VM; Alig S; Alizadeh AA; Gulhane A; Chen DL; Tseng Y; Coye H; Shelby M; Ottemiller S; Keo S; Verni K; Du H; Vandermeer J; Gaston A; Rasmussen H; Martin P; Marzbani E; Voutsinas J; Gopal AK
Blood; 2023 May; 141(21):2576-2586. PubMed ID: 36913694
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Crosswell HE; LaCasce AS; Bartlett NL; Straus DJ; Savage KJ; Zinzani PL; Collins GP; Fanale M; Fenton K; Dong C; Miao H; Grigg AP
Haematologica; 2024 Mar; 109(3):982-987. PubMed ID: 37794803
[No Abstract] [Full Text] [Related]
15. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
Stuver R; Noy A; Vardhana SA; Zelenetz AD; Moskowitz AJ
Br J Haematol; 2024 Feb; 204(2):e17-e20. PubMed ID: 37905372
[No Abstract] [Full Text] [Related]
16. In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869.
Casagrande N; Borghese C; Avanzo M; Aldinucci D
Cells; 2023 Nov; 12(23):. PubMed ID: 38067159
[TBL] [Abstract][Full Text] [Related]
17. Endobronchial Presentation of Hodgkin Lymphoma Responding to Pembrolizumab: A Case Report.
Gentilini M; Casadei B; Morigi A; Lolli G; Ferrari M; Carella M; Argnani L; Zinzani PL
Chemotherapy; 2023; 68(4):219-221. PubMed ID: 37311417
[TBL] [Abstract][Full Text] [Related]
18. Queen's gambit: response-adapted win in CAYA with cHL.
Tolu SS; Amengual JE
Blood; 2023 Apr; 141(17):2037-2038. PubMed ID: 37103949
[No Abstract] [Full Text] [Related]
19. Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.
Okeleji O; Gibson A; Nunez C; Garcia MB; Roth M; Cuglievan B; McCall D
Pediatr Blood Cancer; 2024 Jun; ():e31091. PubMed ID: 38840433
[No Abstract] [Full Text] [Related]
20. Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.
Stuver R; Vardhana SA; Bedmutha A; Chan KK; Mirtcheva-Trocheva R; Nosov A; Schöder H; Moskowitz A
Leuk Lymphoma; 2023 Dec; 64(14):2351-2353. PubMed ID: 37794809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
